Key Findings From Recent Trials

Basic Eldepryl Information

• INN (International Nonproprietary Name): Selegiline (also known as Selegilina, Selegilinum, L‑Deprenalin).
• Brand Names Available In United Kingdom: Eldepryl — tablets 5 mg and 10 mg in blister packs of 28 or 100.
• ATC Code: N04BD01.
• Forms & Dosages: Tablets 5 mg and 10 mg (blisters 28, 100); capsules 5 mg; orally disintegrating tablet 1.25 mg (Zelapar); transdermal patch (Emsam) 6, 9, 12 mg/24 hr.
• Manufacturers In United Kingdom: Sovereign Medical.
• Registration Status In United Kingdom: Prescription only; approved by major regulators including MHRA.
• OTC / Rx Classification: Prescription only (Rx) in the UK.

Major 2022–2025 Studies

What did recent research actually show about selegiline and Parkinson’s disease?

Since 2022 the most robust evidence on selegiline comes from randomised add‑on studies and large observational registries comparing MAO‑B inhibitors in Parkinson’s disease.

These analyses focus on selegiline as an adjunct to levodopa rather than as a disease‑modifying treatment.

Head‑to‑head registry data increasingly feature rasagiline and safinamide as comparators for convenience and broader motor effects.

Randomised add‑on trials show reduced “off” time and slower short‑term levodopa dose escalation when selegiline is used as an adjunct.

Most studies referenced Eldepryl or selegiline tablets when reporting clinical outcomes.

Main Outcomes

What benefits can clinicians and patients expect in the short term?

Selegiline consistently reduces daily “off” time when added to levodopa in early to moderate Parkinson’s disease.

Many trials reported a modest reduction in required levodopa dose escalation over months rather than years.

Once‑daily agents such as rasagiline often match selegiline for motor benefit while offering dosing simplicity.

Overall trial data support selegiline for symptomatic adjunct therapy rather than long‑term neuroprotection.

Safety Observations

Are there new safety signals to worry about?

Pharmacovigilance and trial reports from 2022–2025 reaffirm the established safety profile of selegiline.

Common adverse effects include nausea, insomnia and dry mouth.

Orthostatic hypotension remains a practical concern in older patients on multiple medicines.

Rare hypertensive reactions linked to tyramine or contraindicated drug combinations continue to be reported.

ODT formulations (Zelapar) and transdermal MAO products have prompted renewed attention to onset timing and drug–drug interactions.

Clinical Mechanism Of Action

Layman’s Explanation

How does selegiline help with Parkinson’s symptoms?

Selegiline is a selective MAO‑B inhibitor that helps keep more dopamine available in the brain by blocking its breakdown.

That extra dopamine improves movement control and reduces periods when medication “wears off”.

Patients often notice smoother movement and, in some cases, less need to increase levodopa doses immediately.

At usual doses the drug is used as an adjunct, not as a cure, to manage motor symptoms.

Scientific Breakdown

What happens in the brain when someone takes selegiline?

At therapeutic doses (Eldepryl 5–10 mg tablets; Zelapar ODT 1.25 mg) selegiline preferentially inhibits MAO‑B in the striatum.

Inhibition of MAO‑B reduces dopamine catabolism and increases synaptic dopamine availability.

Metabolism of selegiline produces small amounts of amphetamine metabolites which can contribute to insomnia or agitation in some patients.

Pharmacokinetically, tablets, capsules and ODTs differ in bioavailability and first‑pass metabolism; transdermal MAO formulations are a separate delivery class.

Clinicians should remember that MAO‑B selectivity is dose‑dependent and higher exposure can reduce MAO‑A selectivity, increasing dietary tyramine sensitivity and interaction risk.

Scope Of Approved And Off‑Label Use

United Kingdom Approvals

What is selegiline licensed for in the UK?

Selegiline (Eldepryl) is prescription‑only and approved as an adjunct antiparkinsonian agent (ATC N04BD01).

UK presentations include tablets 5 mg and 10 mg in blister packs (28 or 100).

The drug is routinely included in hospital and primary‑care prescribing for early‑to‑moderate Parkinson’s disease as an adjunct to levodopa/carbidopa.

Packaging and strengths align with standard UK product information and BNF listings.

Notable Off‑Label Trends

Do clinicians use the drug for anything else?

Off‑label use in the UK is limited; transdermal selegiline (Emsam) is licensed for depression in some jurisdictions but not commonly used in UK Parkinson’s pathways.

Some clinicians may consider low‑dose selegiline for older patients where levodopa escalation is problematic, but evidence for neuroprotection remains inconclusive.

Since 2022 there has been a trend towards switching to rasagiline or safinamide for once‑daily convenience or additional mechanisms, while selegiline remains important where cost or local availability dictates.

Dosage Strategy

General Dosing

How is selegiline usually dosed in UK practice?

Standard adult dosing for Parkinson’s disease is 5–10 mg daily, commonly split as 5 mg twice daily.

ODT forms (Zelapar) are typically 1.25–2.5 mg once daily.

Start at the lower end in elderly or frail patients and titrate according to motor response and side effects.

Tablet strengths commonly dispensed are 5 mg and 10 mg; ODT strength is 1.25 mg per tablet.

Condition‑Specific Dosing

How do dosing choices vary by clinical scenario?

As an adjunct to levodopa/carbidopa, selegiline is used to reduce “wearing‑off” and may allow a slower increase in levodopa dose.

Early Parkinson’s may use selegiline as monotherapy or low‑dose adjunct; established disease often uses 5 mg twice daily added to levodopa with monitoring for increased dyskinesia.

Liver or renal impairment requires caution and conservative dosing due to altered clearance.

Pediatric use is not established and therefore not recommended.

Missed dose guidance: take as soon as remembered unless close to the next dose; do not double up.

Overdose can cause severe hypertension, agitation, seizures — seek immediate medical care.

Safety Protocols

Contraindications

Who should not take selegiline?

Absolute contraindications include known hypersensitivity to selegiline or excipients.

Concurrent use with other MAO inhibitors, specific opioids (for example meperidine) or serotonergic agents is contraindicated because of serotonin syndrome or hypertensive crisis risk.

Pheochromocytoma is an absolute contraindication due to severe hypertensive risk.

Relative contraindications requiring close monitoring include severe cardiovascular disease, psychosis or mania, and a history of peptic ulcer disease.

Adverse Effects

What side effects should patients and prescribers expect?

Common mild or moderate effects are nausea, dry mouth, dizziness, insomnia, headache, abdominal pain and increased sweating.

Orthostatic hypotension, agitation and hallucinations occur more often in elderly patients on multiple medications.

Serious but rare events include hypertensive crisis with high tyramine exposure or contraindicated drug combinations, serotonin syndrome and convulsions.

Monitoring and mitigation include baseline cardiovascular review, medicine reconciliation and patient education on potential interactions.

Interaction Mapping

Food Interactions

Do patients need to follow a special diet?

At recommended doses selegiline is MAO‑B selective and dietary restrictions are limited, but higher systemic exposure can reduce selectivity and increase tyramine sensitivity.

Advise patients to be cautious with tyramine‑rich foods such as aged cheeses, cured meats and fermented products if doses are increased or non‑selective MAO inhibition is suspected.

UK guidance usually emphasises practical dietary counselling rather than stringent bans at low doses, while maintaining vigilance for severe headaches or blood pressure spikes.

Drug Combinations To Avoid

Which medicines must not be combined with selegiline?

Avoid combination with non‑selective MAO inhibitors and opioid analgesics like meperidine that risk severe interactions.

Concurrent use with strong serotonergic agents (SSRIs, SNRIs, certain tramadol preparations and triptans) risks serotonin syndrome; ensure appropriate washout periods if switching.

Caution is required with sympathomimetics and sympathomimetic decongestants found in some OTC preparations.

Pharmacists should complete full medicines reconciliation and counsel patients about over‑the‑counter decongestants and herbal remedies.

Patient Experience Analysis

Survey Data

What do patients report about efficacy and tolerability?

UK and European surveys show users report modest motor benefit and delayed levodopa escalation when taking selegiline.

Commonly reported side effects that affect quality of life include insomnia and vivid dreams.

Adherence is generally higher when dosing is simpler; twice‑daily tablet regimens may reduce long‑term persistence compared with once‑daily alternatives.

Clinicians should combine PROMs with motor scales to guide personalised decisions.

Forum Trends

What are people saying on support groups and forums?

Online patient forums highlight three recurring themes: cost and availability, dosing‑form preference and trade‑offs between symptom control and sleep disturbance.

Patients often prefer ODTs like Zelapar when swallowing is an issue, although availability in the UK varies.

Shared decision‑making that records patient preferences about side effects and dosing form works best within UK care pathways.

Distribution And Pricing Landscape

Market Overview

How widely available is Eldepryl in the UK market?

Eldepryl tablets 5 mg and 10 mg are manufactured locally with Sovereign Medical listed as a UK supplier.

Generic competition from global suppliers (Sun Pharma, Teva, Sandoz, Mylan) influences unit pricing in the UK.

Prescription‑only status and NHS formulary listings usually keep patient cost low, though local commissioning decisions can affect access.

For private prescriptions or international purchasing, verify manufacturer and packaging details.

Pricing Trends

What affects price and procurement?

Generic competition has compressed unit prices while newer MAO‑B agents such as rasagiline and safinamide typically cost more and may be chosen for convenience despite the added cost.

Hospital trusts generally procure via national frameworks; community prescribers should consult the BNF and local formularies for current positioning.

Note: in our online pharmacy, eldepryl is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Alternative Options

Comparison Table

Which alternatives are commonly used as adjuncts to levodopa?

Alternatives in the UK include rasagiline and safinamide, both MAO‑B inhibitors, and adjuncts such as COMT inhibitors (entacapone, tolcapone) or dopamine agonists.

Rasagiline typically offers once‑daily dosing with a favourable tolerability profile.

Safinamide provides reversible MAO‑B inhibition plus glutamate modulation that can help motor fluctuations.

Pros And Cons

• Selegiline (Eldepryl): Pros — established evidence base, low cost, multiple formulations; Cons — often twice‑daily dosing, amphetamine metabolites may cause insomnia, interaction risks at higher doses.
• Rasagiline: Pros — once‑daily dosing, similar selectivity; Cons — higher unit cost.
• Safinamide: Pros — reversible inhibition and additional benefit on fluctuations; Cons — newer agent with higher cost.

Regulatory Status

Regulatory Facts

What is selegiline’s legal and regulatory standing in the UK?

Selegiline (Eldepryl) is a prescription‑only medicine approved for Parkinson’s disease (ATC N04BD01).

Pack presentations in the UK include tablets 5 mg and 10 mg in blister packs of 28 or 100.

ODT and transdermal formulations have separate regulatory statuses and indications and require verification via MHRA and the BNF for UK availability.

Post‑Marketing Surveillance

How are adverse events reported and monitored?

MHRA pharmacovigilance continues to monitor events including hypertensive crises and serotonin syndrome.

Clinicians and pharmacists in the UK are encouraged to report suspected reactions via the Yellow Card scheme.

Keep supplier and registration details up to date via MHRA registries and NHS procurement notices.

Consolidated FAQ

Quick Q&A For Prescribers & Patients

What is Eldepryl?

Selegiline — an MAO‑B inhibitor used as an adjunct in Parkinson’s disease.

What is the typical dose?

5–10 mg/day (commonly 5 mg twice daily) for tablets; ODT 1.25–2.5 mg once daily.

Can I eat cheese while taking selegiline?

At standard doses dietary restrictions are limited, but advise caution with high‑tyramine foods if doses increase or if non‑selective MAO inhibition is possible.

Is it safe with SSRIs?

No; avoid concomitant serotonergic agents or ensure appropriate washout to reduce the risk of serotonin syndrome.

How should the medicine be stored?

Keep in original packaging below 25°C, away from moisture and light, and out of reach of children.

What should patients do in an emergency?

Seek immediate medical care for severe headache, chest pain, extreme hypertension, convulsions or signs of serotonin syndrome and report to the MHRA Yellow Card scheme.

Visual Guide

Suggested Figures And Diagrams

Which visuals help explain selegiline to UK patients and clinicians?

A mechanism diagram showing MAO‑B inhibition leading to preserved dopamine is useful for clinics.

A dosing flowchart comparing tablet regimens (5/10 mg split dosing) versus ODT (1.25 mg once daily) and patch options aids prescribing decisions.

An interaction map highlighting contraindicated drugs (SSRIs, meperidine) and tyramine‑rich foods supports safety counselling.

A timeline figure showing typical adjunct initiation and slowed levodopa dose escalation is helpful for shared decision‑making.

Patient‑Facing Infographics

What should a one‑page patient leaflet include?

A simple sheet: “How To Take Eldepryl,” common side effects, foods and medicines to avoid and emergency signs to report.

Use BNF‑style icons, plain English suitable for UK literacy levels, and cite MHRA/BNF sources where possible.

Storage And Transport

Practical Storage

How should Eldepryl be stored in pharmacies and at home?

Store tablets and capsules in original packaging at room temperature below 25°C, protected from moisture and light.

Do not refrigerate or freeze tablets/capsules.

Blister packs help dispensing accuracy; ODT blisters should be kept dry to preserve disintegration.

Transport Considerations

How should stock be handled in UK distribution?

Maintain ambient conditions for short transit; avoid prolonged exposure to high temperatures during summer shipments.

Confirm any special supplier handling requirements for particular formulations and perform stock rotation and expiry checks per MHRA guidance.

For private prescriptions verify manufacturer and batch details before dispensing.

Disposal of returned or expired medicines should follow local NHS protocols; do not flush medications.

Guidelines For Proper Use

Prescriber Checklist

What steps should prescribers complete before starting selegiline?

Confirm Parkinson’s diagnosis and indication for adjunct therapy.

Perform full medication review to exclude contraindicated agents such as other MAOIs, opioids like meperidine and strong serotonergic drugs.

Complete baseline blood pressure and cardiovascular assessment.

Discuss dosing form (tablets 5–10 mg or ODT 1.25 mg) and consider starting at 5 mg with planned titration.

Document counselling and a monitoring plan in the patient record.

Patient Counselling Points

What should patients be told at the pharmacy or clinic?

Explain the purpose as adjunct symptom control and emphasise not to double doses.

Advise on common side effects, especially insomnia and orthostatic symptoms, and instruct on when to seek urgent care.

Discuss food cautions for tyramine in certain scenarios and advise to report new medications, including OTC products.

Plan a clinical review within 4–12 weeks of initiation and routine monitoring thereafter.

Delivery Across United Kingdom